论文部分内容阅读
目的 :探讨EML4-ALK融合基因在新疆维吾尔族NSCLC患者中的表达及其对预后的影响。方法 :应用免疫组化法及FISH法检测新疆维吾尔族和汉族NSCLC患者EML4-ALK融合基因表达情况,并分析新疆维吾尔族NSCLC患者EML4-ALK融合基因表达与临床病理特征的关系及对预后的影响。结果 :新疆维吾尔族、汉族NSCLC患者EML4-ALK融合基因表达阳性表达率分别为21.00%、9.00%,经统计学检验发现不同民族NSCLC患者EML4-ALK融合基因阳性表达率存在统计学差异,新疆维吾尔族NSCLC患者EML4-ALK融合基因阳性表达率明显高于汉族;新疆维吾尔族NSCLC患者EML4-ALK融合基因表达与年龄、性别、吸烟、临床分期、病理切片类型有关,年龄≤55岁、女性、不吸烟、临床分期高、病理切片类型为腺癌的新疆维吾尔族NSCLC患者EML4-ALK融合基因阳性表达率较高;EML4-ALK融合基因阳性表达的新疆维吾尔族NSCLC患者中位总生存时间为22个月(95%CI,11个月~26个月),不同EML4-ALK融合基因表达总生存时间没有统计学差异。结论 :新疆维吾尔族NSCLC患者EML4-ALK融合基因阳性表达率较高,多见于年龄≤55岁、女性、不吸烟、临床分期高、病理切片类型为腺癌者,但EML4-ALK融合基因还不能作为独立的预后影响因素。
Objective: To investigate the expression of EML4-ALK fusion gene in Uygur NSCLC patients and its effect on prognosis. Methods: The expression of EML4-ALK fusion gene in Uighur and Han nationality patients with NSCLC was detected by immunohistochemistry and FISH. The relationship between EML4-ALK fusion gene expression and clinicopathological features and the prognosis of NSCLC patients were analyzed. . Results: The positive expression rates of EML4-ALK fusion gene in NSCLC patients were 21.00% and 9.00% respectively in Xinjiang Uygur and Han nationalities. The positive rates of EML4-ALK fusion gene expression among NSCLC patients from different ethnic groups were statistically significant The positive expression rate of EML4-ALK fusion gene in NSCLC patients was significantly higher than that in Han nationality. The expression of EML4-ALK fusion gene in NSCLC patients was related to age, sex, smoking, clinical stage and pathological type. The positive rate of EML4-ALK fusion gene was higher in Uighur NSCLC patients with smoking, high clinical stage and pathological type of adenocarcinoma. The median overall survival time of Xinjiang Uygur NSCLC patients with EML4-ALK fusion gene expression was 22 Month (95% CI, 11 months to 26 months), there was no statistical difference in the overall survival of different EML4-ALK fusion gene expression. CONCLUSIONS: The positive expression rate of EML4-ALK fusion gene in NSCLC patients is higher in Xinjiang Uygur nationality. The EML4-ALK fusion gene is more common in women aged less than 55 years, with high clinical stage and pathological type of adenocarcinoma. However, As an independent prognostic factor.